Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and Brain Irradiation in Metastatic Breast Cancer
NCT02563925Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2015
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Open-label, single-arm trial of tremelimumab in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression Free Survival (irPFS) at 12 weeks. Started Sep 2015; status: completed.
02
Drugs
tremelimumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02563925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563925.